Where can I find news about FSGS?

Press releases, SEC filings, and prospectus updates from the fund issuer are listed on this page. First Trust SMID Growth Strength ETF (FSGS) news is sourced from regulatory filings and the issuer's investor relations feed.

How can I track FSGS's SEC filings?

FSGS's 485APOS / 485BPOS prospectus filings, N-CSR shareholder reports, and other regulatory filings are listed on this page with direct links to the SEC EDGAR copies. Filings update as the issuer submits them, typically semi-annually for shareholder reports.

Where can I find FSGS's prospectus?

First Trust SMID Growth Strength ETF (FSGS)'s most recent prospectus is linked in the filings section on this page. Issuers publish the full prospectus on their product page and re-file it annually with material updates flagged in the 485BPOS amendment.

FSGS

First Trust SMID Growth Strength ETF

NASDAQ·Asset Management · Financial Services

$33.04$0.46−1.37%

After hours·$33.01−0.10%

Market closed·Oct 30 4:00 PM EDT

News & Analysis

CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseasesPR NewswireMELBOURNE, Australia and BASEL,
gurufocus.comOct 4, 2026 · 6:00 PM
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental G
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Paten
gurufocus.comSep 23, 2026 · 8:00 AM
Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib
HONG KONG, July 8, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced the closing of its previously announced exclusive licensing and collaborat
gurufocus.comJul 8, 2026 · 1:00 AM
Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion
HONG KONG, June 4, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreemen
gurufocus.comJun 4, 2026 · 12:00 AM
Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines f
gurufocus.comJun 2, 2026 · 8:00 AM

Fund Documents

SEC filings for FSGS aren't indexed yet (common for recently launched funds). Browse the issuer's filings on SEC EDGAR directly.

Frequently Asked Questions About FSGS

Where can I find news about FSGS?: Press releases, SEC filings, and prospectus updates from the fund issuer are listed on this page. First Trust SMID Growth Strength ETF (FSGS) news is sourced from regulatory filings and the issuer's investor relations feed.
How can I track FSGS's SEC filings?: FSGS's 485APOS / 485BPOS prospectus filings, N-CSR shareholder reports, and other regulatory filings are listed on this page with direct links to the SEC EDGAR copies. Filings update as the issuer submits them, typically semi-annually for shareholder reports.
Where can I find FSGS's prospectus?: First Trust SMID Growth Strength ETF (FSGS)'s most recent prospectus is linked in the filings section on this page. Issuers publish the full prospectus on their product page and re-file it annually with material updates flagged in the 485BPOS amendment.

First Trust SMID Growth Strength ETF

Frequently Asked Questions About FSGS

First Trust SMID Growth Strength ETF

CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental G

Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib

Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion

Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases

Frequently Asked Questions About FSGS

CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental G

Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib

Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion

Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases